Pre-Clinical
Phase I
Phase II
Indication
CAR-T
(Expand to Multiple Cancer Types)
NT-1921
Phase I (IIT) in progress
Prostate Cancer
NT-2022
Phase I (IIT)
Hematological Malignancy
NT-1921, powered by the SMART technology, is an innovative solution to treat prostate cancer.
- Modulate immune activity of tumor micro environment (TME) by activating tumor-infiltrating lymphocytes(TILs) activity and reducing regulatory T cell (Treg) population in TME
- Improve CAR-T cell proliferation and persistence while minimizing potential systemic side effects
- Enhance the effectiveness of killing cancer cells due to cytokine release & accumulation in TME
- Phase I investigator-initiated trials (NCT05656573) for mCRPC (Metastatic castration-resistant prostate cancer) demonstrated high safety and high efficacy (DCR 100% and ORR30 62% with > 30% decline in serum PSA)
- Potential to re-sensitizing the first-line antiandrogen drugs for mCRPC patients, such as Xtandi (enzalutamide), Erleada (apalutamide), Casodex (bicalutamide) etc.
NT-2022, specifically targeting to B-cell malignancies, is an innovative CAR-T therapy for Hematological Malignancy (ALL, CLL & NHL) and autoimmune diseases
- Modulate immune activity of tumor micro-environment (TME)
- Efficiently block tumor & TME immune checkpoint
- Improve therapeutic activity compared to conventional CAR-T by enhancement of CAR-T cell proliferation and persistence
- Unleash the full anti-tumor potential of CAR-T cell
- Reduce risk of systemic toxicity